Age-Related Eye Disease Study (AREDS)

Age-Related Eye Disease Study (AREDS)
Name	Age-Related Eye Disease Study
Acronym	AREDS
Field	Ophthalmology
Sponsor	National Eye Institute
Start	1992
End	2001
Participants	4,757
Location	United States

Age-Related Eye Disease Study (AREDS) The Age-Related Eye Disease Study was a multi-center clinical trial funded by the National Institutes of Health and conducted by the National Eye Institute that evaluated nutritional supplementation and risk factors for advanced age-related macular degeneration and cataract in older adults. The trial enrolled thousands of participants at clinical centers across the United States and produced widely cited results that influenced recommendations by professional bodies such as the American Academy of Ophthalmology and agencies including the U.S. Food and Drug Administration.

Background and Objectives

AREDS was launched against a backdrop of growing public health concern about age-related macular degeneration and visual impairment in aging populations, with participation from institutions like the Mayo Clinic, the Johns Hopkins Hospital, the Massachusetts Eye and Ear Infirmary, and the University of Wisconsin School of Medicine and Public Health. Principal investigators included clinicians and researchers affiliated with the National Eye Institute, the National Institutes of Health, the Harvard Medical School, and the University of Southern California. Objectives were to quantify progression risk of late-stage age-related macular degeneration and to test whether high-dose antioxidant and mineral supplementation could reduce progression to neovascular wet macular degeneration or central geographic atrophy, as well as to evaluate effects on lens opacities (cataracts). The study sought to inform guideline panels such as those convened by the American Optometric Association and the American Academy of Ophthalmology.

Study Design and Methods

AREDS was a randomized, placebo-controlled clinical trial with factorial design executed at multiple clinical centers including the Wilmer Eye Institute and the Scheie Eye Institute. Enrollment criteria drew from epidemiologic cohorts and eye clinics associated with institutions like the University of Pennsylvania and the University of Michigan, targeting adults with varying grades of macular degeneration and lens changes. Methods included standardized fundus photography protocols developed in collaboration with the Early Treatment Diabetic Retinopathy Study investigators, grading at centralized reading centers, and outcome adjudication by committees with members from the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. Statistical analysis plans referenced methods used by trials such as the Diabetes Control and Complications Trial and incorporated survival analysis and intent-to-treat principles familiar from randomized trials at the National Institutes of Health.

Supplement Formulations and Interventions

Interventions tested in AREDS included a combination of high-dose antioxidants and minerals: beta-carotene, vitamin C, vitamin E, and zinc with copper, reflecting biologic hypotheses derived from work at institutions like the Salk Institute and the Broad Institute on oxidative stress. Formulations were chosen with input from advisory panels involving scientists from the National Eye Institute, the Food and Nutrition Board of the Institute of Medicine, and pharmaceutical or supplement manufacturers regulated by the U.S. Food and Drug Administration. The study compared arms receiving the antioxidant formulation, zinc alone, combined antioxidant plus zinc, and placebo, while monitoring adverse events and interactions relevant to populations served by centers such as Massachusetts General Hospital and Cedars-Sinai Medical Center.

Key Findings and Outcomes

AREDS reported that the combined antioxidant plus zinc formulation reduced the 5-year risk of progression to advanced age-related macular degeneration among participants at high baseline risk (categories defined by photographic grading) compared with placebo. Findings were published and discussed in venues including the New England Journal of Medicine and presented at meetings of the Association for Research in Vision and Ophthalmology and the American Academy of Ophthalmology. Secondary outcomes included analyses of cataract incidence and adverse effects, with subgroup analyses referencing cohorts from the Framingham Heart Study and similar epidemiologic studies. The trial also highlighted safety signals such as increased lung cancer risk associated with beta-carotene among current and former smokers, echoing concerns raised in trials like the Beta-Carotene and Retinol Efficacy Trial.

Impact on Clinical Practice and Guidelines

AREDS results informed clinical recommendations by organizations such as the American Academy of Ophthalmology, the American Optometric Association, and guideline panels convened by the U.S. Preventive Services Task Force and influenced product labeling by manufacturers regulated by the U.S. Food and Drug Administration. Ophthalmologists at centers like the Bascom Palmer Eye Institute and the Wills Eye Hospital incorporated AREDS-derived formulations into management pathways for patients with intermediate or advanced unilateral age-related macular degeneration. Public health messaging by agencies including the Centers for Disease Control and Prevention and professional societies emphasized targeted use of supplementation rather than population-wide administration, and practice patterns were further shaped by economic analyses from institutions like the Harvard School of Public Health.

Subsequent Research and AREDS2 Follow-up

Following AREDS, investigators and collaborators from institutions such as the University of California, San Francisco, the Bascom Palmer Eye Institute, and the Johns Hopkins University designed follow-up studies, notably AREDS2, to evaluate lutein, zeaxanthin, and omega-3 fatty acids and to reassess beta‑carotene risks in smokers. AREDS2 results, published and discussed at forums including the American Academy of Ophthalmology annual meeting and incorporated into updates by the National Eye Institute, refined supplement formulations and informed newer guidelines; subsequent research has included genetic association studies drawing on data from consortia such as the International AMD Genomics Consortium and interventional trials at centers like the Moorfields Eye Hospital and the University College London Institute of Ophthalmology. Together, AREDS and AREDS2 have become reference points for clinical trials in ophthalmology and for translational collaborations across institutions such as the National Institutes of Health, major academic medical centers, and international research networks.

Category:Clinical trials in ophthalmology